Janne Hukkanen1,2,3,4, Johanna Puurunen4,5,6, Tuulia Hyötyläinen7, Markku J Savolainen1,2,3,4, Aimo Ruokonen8,9, Laure Morin-Papunen4,5,6, Matej Orešič7, Terhi Piltonen4,5,6, Juha S Tapanainen4,5,6,10. 1. Research Center for Internal Medicine, University of Oulu, Oulu. 2. Department of Internal Medicine, Oulu University Hospital, Oulu. 3. Biocenter Oulu, Oulu. 4. Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulo. 5. Department of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of Oulu, Oulu. 6. Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulo, Finland. 7. Steno Diabetes Center, Gentofte, Denmark. 8. Department of Clinical Chemistry, Institute of Diagnostics, University of Oulu, Oulu. 9. NordLab Oulu, Oulu University Hospital, Oulu. 10. Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Abstract
AIMS: Atorvastatin is known to both inhibit and induce the cytochrome P450 3A4 (CYP3A4) enzyme in vitro. Some clinical studies indicate that atorvastatin inhibits CYP3A4 but there are no well-controlled longer term studies that could evaluate the inducing effect of atorvastatin. We aimed to determine if atorvastatin induces or inhibits CYP3A4 activity as measured by the 4β-hydroxycholesterol to cholesterol ratio (4βHC : C). METHODS: In this randomized, double-blind, placebo-controlled 6 month study we evaluated the effects of atorvastatin 20 mg day(-1) (n = 15) and placebo (n = 14) on oxysterol concentrations and determined if atorvastatin induces or inhibits CYP3A4 activity as assessed by the 4βHC : C index. The respective 25-hydroxycholesterol and 5α,6α-epoxycholesterol ratios were used as negative controls. RESULTS: Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. The mean 4βHC : C ratio decreased by 13% (0.214 ± 0.04 to 0.182 ± 0.04, P = 0.024, 95% confidence interval (CI) of the difference -0.0595, -0.00483) in the atorvastatin group while no significant change occurred in the placebo group. The difference in change of 4βHC : C between study arms was statistically significant (atorvastatin -0.032, placebo 0.0055, P = 0.020, 95% CI of the difference -0.069, -0.0067). The ratios of 25-hydroxycholesterol and 5α,6α-epoxycholesterol to cholesterol did not change. CONCLUSIONS: The results establish atorvastatin as an inhibitor of CYP3A4 activity. Furthermore, 4βHC : C is a useful index of CYP3A4 activity, including the conditions with altered cholesterol concentrations.
RCT Entities:
AIMS: Atorvastatin is known to both inhibit and induce the cytochrome P450 3A4 (CYP3A4) enzyme in vitro. Some clinical studies indicate that atorvastatin inhibits CYP3A4 but there are no well-controlled longer term studies that could evaluate the inducing effect of atorvastatin. We aimed to determine if atorvastatin induces or inhibits CYP3A4 activity as measured by the 4β-hydroxycholesterol to cholesterol ratio (4βHC : C). METHODS: In this randomized, double-blind, placebo-controlled 6 month study we evaluated the effects of atorvastatin 20 mg day(-1) (n = 15) and placebo (n = 14) on oxysterol concentrations and determined if atorvastatin induces or inhibits CYP3A4 activity as assessed by the 4βHC : C index. The respective 25-hydroxycholesterol and 5α,6α-epoxycholesterol ratios were used as negative controls. RESULTS: Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. The mean 4βHC : C ratio decreased by 13% (0.214 ± 0.04 to 0.182 ± 0.04, P = 0.024, 95% confidence interval (CI) of the difference -0.0595, -0.00483) in the atorvastatin group while no significant change occurred in the placebo group. The difference in change of 4βHC : C between study arms was statistically significant (atorvastatin -0.032, placebo 0.0055, P = 0.020, 95% CI of the difference -0.069, -0.0067). The ratios of 25-hydroxycholesterol and 5α,6α-epoxycholesterol to cholesterol did not change. CONCLUSIONS: The results establish atorvastatin as an inhibitor of CYP3A4 activity. Furthermore, 4βHC : C is a useful index of CYP3A4 activity, including the conditions with altered cholesterol concentrations.
Authors: Diana M Feidt; Kathrin Klein; Ute Hofmann; Stephan Riedmaier; Daniel Knobeloch; Wolfgang E Thasler; Thomas S Weiss; Matthias Schwab; Ulrich M Zanger Journal: Drug Metab Dispos Date: 2010-06-15 Impact factor: 3.922
Authors: C G Mc Donnell; S Harte; J O'Driscoll; C O'Loughlin; F N A M Van Pelt; G D Shorten; F D Van Pelt Journal: Anaesthesia Date: 2003-09 Impact factor: 6.955
Authors: Maria Alice V Willrich; Alice C Rodrigues; Alvaro Cerda; Fabiana D V Genvigir; Simone S Arazi; Egidio L Dorea; Marcia M S Bernik; Marcelo C Bertolami; Andre Faludi; Alvaro Largura; Linnea M Baudhuin; Sandra C Bryant; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata Journal: Clin Chim Acta Date: 2013-03-15 Impact factor: 3.786
Authors: Sauzanne Khalilieh; Ka Lai Yee; Rosa I Sanchez; Ilias Triantafyllou; Li Fan; Noha Maklad; Heather Jordan; Maureen Martell; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Ingrid Škorňová; Matej Samoš; Tomáš Bolek; Lucia Stančiaková; Ľubica Vádelová; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň Journal: Pharmacol Res Perspect Date: 2021-05
Authors: Stefania Cicolari; Chiara Pavanello; Elena Olmastroni; Marina Del Puppo; Marco Bertolotti; Giuliana Mombelli; Alberico L Catapano; Laura Calabresi; Paolo Magni Journal: Nutrients Date: 2021-01-28 Impact factor: 5.717